Synthesis, in vitro, and in cell studies of a new series of [Indoline-3,2′-thiazolidine]-based p53 modulators

Journal of Medicinal Chemistry

Volumn 56, Issue 13, 2013, Pages 5407-5421

  Bertamino, Alessia ^a   Soprano, Maria ^b   Musella, Simona ^a   Rusciano, Maria Rosaria ^b   Sala, Marina ^a   Vernieri, Ermelinda ^a   Di Sarno, Veronica ^a   Limatola, Antonio ^b   Carotenuto, Alfonso ^b   Cosconati, Sandro ^c   Grieco, Paolo ^b   Novellino, Ettore ^b   Illario, Maddalena ^b   Campiglia, Pietro ^a   Gomez Monterrey, Isabel ^b  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 3' (CYCLOHEXANECARBONYL) 1 METHYL 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ANTINEOPLASTIC AGENT; ETHYL 1 (4 CHLOROBENZOYL) 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 1 (4 CHLOROBENZOYL) 5 METHYL 2 OXO 5' H SPIRO[INDOLINE 3,2' THIAZOLE] 4 CARBOXYLATE; ETHYL 1 (4 CHLOROBENZOYL) 5 METHYL 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 3' (2 (4 CHLOROPHENYLACETYL) 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE 4 CARBOXYATE; ETHYL 3' (4 CHLOROBENZOYL) 1 METHYL 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 3' (4 CHLOROBENZOYL) 1,5 DIMETHYL 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 3' (4 CHLOROBENZOYL) 2 OXOSPIRO[INDOLINE 3,2 THIAZOLIDINE] 4' CARBOXYLATE; ETHYL 3' (4 CHLOROBENZOYL) 5 METHYL 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 3' (CYCLOHEXANECARBONYL) 1 METHYL 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 BROMO 1 (4 CHLOROBENZOYL) 2 OXO 5 H SPIRO[INDOLINE 3,2' THIAZOLE] 4 CARBOXYLATE; ETHYL 5 BROMO 1 (4 CHLOROBENZOYL) 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 BROMO 1 (CYCLOHEXANECARBONYL) 2 OXO 5 H SPIRO[INDOLINE 3,2' THIAZOLE] 4 CARBOXYLATE; ETHYL 5 BROMO 1 (CYCLOHEXANECARBONYL) 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 BROMO 1 METHYL 3' (4 METHYLBENZOYL) 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 BROMO 3 (4 CHLOROBENZOYL) 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4' CARBOXYLATE; ETHYL 5 BROMO 3 BROMO 3' BENZOYL 1 METHYL 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 BROMO 3' (2 (4 CHLOROPHENYL)ACETYL) 1 METHYL 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 BROMO 3' (2 (4 CHLOROPHENYL)ACETYL) 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 BROMO 3' (4 CHLOROBENZOYL) 1 METHYL 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 BROMO 3' (CYCLOHEXANECARBONYL) 1 METHYL 2 OXOSPIRO[INDOLINE 3,2 THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 BROMO 3' (CYCLOHEXANECARBONYL) 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 METHYL 3' (2 (4 CHLOROPHENYL)ACETYL) 2 OXOSPIRO[INDOLINE 3,2 THIAZOLIDINE] 4 CARBOXYLATE; ETHYL 5 METHYL 3' (CYCLOHEXANECARBONYL) 1 METHYL 2 OXOSPIRO[INDOLINE 3,2' THIAZOLIDINE] 4 CARBOXYLATE; PROTEIN P53; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN HT29; COLON CARCINOMA; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MOLECULAR MODEL; STEREOCHEMISTRY; TUMOR CELL LINE;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HEP G2 CELLS; HUMANS; MCF-7 CELLS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; THIAZOLIDINES; TUMOR SUPPRESSOR PROTEIN P53; U937 CELLS;

EID: 84880165688     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400311n     Document Type: Article

References (54)

1. Levine, J.; Oren, M. The first 30 years of p53: Growing ever more complex Nat. Rev. Cancer 2009, 9, 749-758
2. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network Nature 2000, 408, 307-310
3. Vousden, K. H.; Prives, C. Blinded by the light: the growing complexity of p53 Cell 2009, 137, 413-431
4. Feng, Z.; Wu, R.; Lin, M.; Hu, W. Tumor suppressor p53: new functions of an old protein Front. Biol. 2011, 6, 58-68
5. Maddocks, O. D. K.; Vousden, K. H. Metabolic regulation by p53 J. Mol. Med. 2011, 89, 237-245
6. Muller, P. A. J.; Vousden, K. H.; Norman, J. C. p53 and its mutants in tumor cell migration and invasion J. Cell Biol. 2011, 192, 209-218 and references therein
7. Yang, Y.; Li, C. C.; Weissman, A. M. Regulating the p53 system through ubiquitination Oncogene 2004, 23, 2096-2106
8. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. The mdm-2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation Cell 1992, 69, 1237-1245
9. Geyer, R. K.; Yu, Z. K.; Maki, C. G. The MDM2 RING-finger domain is required to promote p53 nuclear export Nat. Cell Biol. 2000, 2, 569-73
10. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53 Nature 1997, 387, 296-299
11. Levine, A. p53, the cellular gatekeeper for growth and division Cell 1997, 88, 323-331
12. Greenblatt, M. S.; Bennett, W. P.; Hollstein, M.; Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res. 1994, 54, 4855-4878
13. Fakharzadeh, S. S.; Trusko, S. P.; George, D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line EMBO J. 1991, 10, 1565-1569
14. Oliner, J. D.; Kinzler, K. W.; Meltzer, P. S.; George, D. L.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas Nature 1992, 358, 80-83
15. Jones, S. N.; Hancock, A. R.; Vogel, H.; Donehower, L. A.; Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15608-15612
16. Ventura, A.; Kirsch, D. G.; McLaughlin, M. E.; Tuveson, D. A.; Grimm, J.; Lintault, L.; Newman, J.; Reczek, E. E.; Weissleder, R.; Jacks, T. Restoration of p53 function leads to tumor regression in vivo Nature 2007, 445, 661-665
17. Xue, W.; Zender, L.; Miething, C.; Dickins, R. A.; Hernando, E.; Krizhanovsky, V.; Cordon-Cardo, C.; Lowe, S. W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas Nature 2007, 445, 656-660
18. Brown, C. J.; Lain, S.; Verma, C. S.; Fersht, A. R.; Lane, D. P. Awakening guardian angels: drugging the p53 pathway Nat. Rev. Cancer 2009, 9, 862-873
19. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy Nat. Rev. Cancer 2003, 3, 102-109
20. Hardcastle, I. R. Inhibitors of the MDM2-p53 interaction as anticancer drugs Drugs Future 2007, 32, 883-896
21. Fischer, P. Peptide, peptidomimetic, and small-molecule antagonists of the p53-HDM2 protein-protein interaction Int. J. Pept. Res. Ther. 2006, 12, 3-19
22. Shangary, S.; Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy Ann. Rev. Pharmacol. Toxicol 2009, 49, 223-241
23. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004, 303, 844-848
24. Grasberger, B. L.; Lu, T. B.; Schubert, C.; Parks, D. J.; Carver, T. E.; Koblish, H. K.; Cummings, M. D.; LaFrance, L. V.; Milkiewicz, K. L.; Calvo, R. R.; Maguire, D.; Lattanze, J.; Franks, C. F.; Zhao, S. Y.; Ramachandren, K.; Bylebyl, G. R.; Zhang, M.; Manthey, C. L.; Petrella, E. C.; Pantoliano, M. W.; Deckman, I. C.; Spurlino, J. C.; Maroney, A. C.; Tomczuk, B. E.; Molloy, C. J.; Bone, R. F. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells J. Med. Chem. 2005, 48, 909-912
25. Koblish, H. K.; Zhao, S. Y.; Franks, C. F.; Donatelli, R. R.; Tominovich, R. M.; LaFrance, L. V.; Leonard, K. A.; Gushue, J. M.; Parks, D. J.; Calvo, R. R.; Milkiewicz, K. L.; Marugan, J. J.; Raboisson, P.; Cummings, M. D.; Grasberger, B. L.; Johnson, D. L.; Lu, T. B.; Molloy, C. J.; Maroney, A. C. Benzodiazepinedione inhibitors of the Hdm2: p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo Mol. Cancer Ther. 2006, 5, 160-169
26. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Qui, S.; Ding, Y.; Gao, W.; Stuckey, J.; Krajewski, K.; Roller, P. P.; Tomita, Y.; Parrish, D. A.; Deschamps, J. R.; Wang, S. Structure-based design of potent non-peptide MDM2 inhibitors J. Am. Chem. Soc. 2005, 127, 10130-10131
27. Yu, S.; Qin, D.; Shangary, S.; Chen, J.; Wang, G.; Ding, K.; McEachern, D.; Qiu, S.; Nikolovska-Coleska, Z.; Miller, R.; Kang, S.; Yang, D.; Wang, S. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction J. Med. Chem. 2009, 52, 7970-7973
28. Allen, J. G.; Bourbeau, M. P.; Wohlhieter, G. E.; Bartberger, M. D.; Michelsen, K.; Hungate, R.; Gadwood, R. C.; Gaston, R. D.; Evans, B.; Mann, L. W.; Matison, M. E.; Schneider, S.; Huang, X.; Yu, D.; Andrews, P. S.; Reichelt, A.; Long, A. M.; Yakowec, P.; Yang, E. Y.; Lee, T. A.; Oliner, J. D. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction J. Med. Chem. 2009, 52, 7044-7053
29. Hardcastle, I. R.; Ahmed, S. U.; Atkins, H.; Farnie, G.; Golding, B. T.; Griffin, R. J.; Guyenne, S.; Hutton, C.; Kallblad, P.; Kemp, S. J.; Kitching, M. S.; Newell, D. R.; Norbedo, S.; Northen, J. S.; Reid, R. J.; Saravanan, K.; Willems, H. M. G.; Lunec, J. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold J. Med. Chem. 2006, 49, 6209-6221
30. Hardcastle, I. R.; Junfeng Liu, J.; Valeur, E.; Watson, A.; Ahmed, S. U.; Blackburn, T. J.; Bennaceur, K.; Clegg, W.; Drummond, C.; Endicott, J. A.; Golding, B. T.; Griffin, R. J.; Gruber, J.; Haggerty, K.; Harrington, R. W.; Hutton, C.; Kemp, S.; Lu, X.; McDonnell, J. M.; Newell, D. R.; Noble, M. E. M.; Payne, S. L.; Revill, C. H.; Riedinger, C.; Xu, Q.; Lunec, J. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency J. Med. Chem. 2011, 54, 1233-1243
31. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 1996, 274, 948-953
32. Lee, H.; Mok, K. H.; Muhandiram, R.; Park, K. H.; Suk, J. E.; Kim, D. H.; Chang, J.; Sung, Y. C.; Choi, K. Y.; Han, K. H. Local structural elements in the mostly unstructured transcriptional activation domain of human p53 J. Biol. Chem. 2000, 275, 29426-29432
33. Murray, J. K.; Gellman, S. H. Targeting protein-protein interactions: lessons from p53/MDM2 Biopolymers 2007, 88, 657-686
34. Shangary, S.; Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy Annu. Rev. Pharmacol. Toxicol. 2009, 49, 223-241
35. Gomez-Monterrey, I.; Bertamino, A.; Porta, A.; Carotenuto, A.; Musella, S.; Aquino, C.; Granata, I.; Sala, M.; Brancaccio, D.; Picone, D.; Ercole, C.; Stiuso, P.; Campiglia, P.; Grieco, P.; Ianelli, P.; Maresca, B.; Novellino, E. Identification of the spiro(oxindole-3,3′-thiazolidine)-based derivatives as potential p53 activity modulators J. Med. Chem. 2010, 53, 8319-8329
36. Bertamino, A.; Aquino, C.; Sala, M.; de Simone, N.; Mattia, C. A.; Erra, L.; Musella, S.; Iannelli, P.; Carotenuto, A.; Grieco, P.; Novellino, E.; Campiglia, P.; Gomez- Monterrey, I. Design and synthesis of spirotryprostatin- inspired diketopiperazine systems from prolyl spirooxoindolethiazolidine derivatives Bioorg. Med. Chem. 2010, 18, 4328-4337
37. Szilagyi, L.; Gyorgydeak, Z. Comments on the putative stereoselectivity in cysteine-aldehyde reactions. Selective C(2) inversion and C(4) epimerization in thiazolidine-4-carboxylic acids J. Am. Chem. Soc. 1979, 101, 427-432
38. Deroose, F. D; De Clercq, J. Novel enantioselective syntheses of (+)-biotin J. Org. Chem. 1995, 60, 321-330
39. Neuhaus, D.; Williamson, M. P. The Nuclear Overhauser Effect in Structural and Conformational Analysis; Wiley-VCH: New York, 2000.
40. Arva, N. C.; Talbott, K. E.; Okoro, D. R.; Brekman, A.; Qiu, W. G.; Bargonetti, J. Disruption of the p53-Mdm2 complex by nutlin-3 reveals different cancer cell phenotypes Ethnicity Dis. 2008, 18 (S2) 1-8
41. Supiot, S.; Hill, R. P.; Bristow, R. G. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53 Mol. Cancer Ther. 2008, 7, 993-999
42. Zheng, T.; Jiabei Wang, J.; Song, X.; Meng, X.; Pan, S.; Jiang, H.; Liu, L. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways J. Cancer Res. Clin. Oncol. 2010, 136, 1597-1604
43. Popowicz, G. M.; Czarna, A.; Wolf, S.; Wang, K.; Wang, W.; Dömling, A.; Holak, T. A. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery Cell Cycle 2010, 9, 1104-1111
44. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A semiempirical free energy force field with charge-based desolvation J. Comput. Chem. 2007, 28, 1145-1152
45. Cosconati, S.; Forli, S.; Perryman, A. L.; Harris, R.; Goodsell, D. S.; Olson, A. J. Virtual screening with AutoDock: theory and practice Expert Opin. Drug Discovery 2010, 5, 597-607
46. Gonzalez-Lopez de Turiso, F.; Sun, D.; Rew, Y.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Correll, T. L.; Huang, X.; Julian, L. D.; Kayser, F.; Lo, M. C.; Long, A. M.; McMinn, D.; Oliner, J. D.; Osgood, T.; Powers, J. P.; Saiki, A. Y.; Schneider, S.; Shaffer, P.; Xiao, S. H.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Medina, J. C.; Olson, S. H. Rational design and binding mode duality of MDM2-p53 inhibitors. J. Med. Chem. 2013, in press.
47. Vousden, K. H.; Xin, Lu, X. Live or let die: the cell's response to p53 Nat. Rev. Cancer 2002, 2, 594-604
48. Haupt, S.; Berger, M.; Goldberg, Z.; Haupt, Y. Apoptosis-the p53 network J. Cell Sci. 2003, 116, 4077-4085
49. Pietsch, E. C.; Sykes, S. M.; McMahon, S. B.; Murphy, M. E. The p53 family and programmed cell death Oncogene 2008, 27, 6507-6521
50. Hori, T.; Kondo, T.; Kanamori, M.; Tabuchi, Y.; Ogawa, R.; Zhao, Q.-L.; Ahmed, K.; Yasuda, T.; Seki, S.; Suzuki, K.; Kimura, T. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells Cancer Lett. 2010, 287, 98-108
51. Tseng, H.-Y.; Jiang, C. C.; Croft, A.; Tay, K. H.; Thorne, R. F.; Fan Yang, F.; Liu, H.; Hersey, P.; Zhang, X. D. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells Mol. Cancer Ther. 2010, 9, 3363-3374
52. Bax, A.; Davis, D. G. 2D ROESY with cw spinlock for mixing phase sensitive using States-TPPI method J. Magn. Reson. 1985, 63, 207-213
53. States, D. J.; Haberkorn, R. A.; Ruben, D. J. A two-dimensional nuclear Overhauser experiment with pure absorption phase four quadrants J. Magn. Reson. 1982, 48, 286-292
54. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612 e Ricerca